Full-Time

Strategic Account Manager

Invivyd

Invivyd

51-200 employees

Develops monoclonal antibodies for viral protection

Compensation Overview

$152k - $202k/yr

+ Short-term incentive + Equity

South Carolina, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Requirements
  • Bachelor's degree strongly preferred; candidates without a degree with significant relevant, related industry experience will be considered
  • At least 10+ years of experience in sales in biotech, pharmaceuticals or medical device customer-facing roles is required
  • Candidates must live within the stated territory
  • Able to fulfill requirement to be in the field five days a week, including overnights as required, conducting visits, while also completing all administrative tasks related to the role
  • Ability to drive and/or fly within the territory, as required
  • Proven winning attitude with a growth mindset
  • Strong communication and interpersonal skills, with the ability to build relationships and engage in meaningful conversations with healthcare providers
  • Coachable and eager to learn - open to feedback, willing to adapt, and motivated to grow into a high-performing sales professional
  • Demonstrated persistence, resilience, agility, and a strong work ethic; comfortable working in a fast-paced, evolving environment
  • Ability to manage time effectively, prioritize tasks, and take ownership of territory responsibilities
  • High standards of integrity, professionalism, and a commitment to compliance in every interaction
  • Passion for making a difference in the lives of patients and a desire to be part of a mission-driven company
  • Strong ability to communicate clinical product information in a compelling and compliant way
  • Must be results oriented and can demonstrate time management skills with ability to gain access to hard to see customers
  • Demonstrated effective organizational and interpersonal skills to prioritize opportunities
Responsibilities
  • Develop strong, compliant relationships across a broad range of health care providers (HCPs) across multiple specialties and account types (IDNs, health systems and community clinics) by understanding their needs and sharing accurate, balanced information about Invivyd’s products and solutions
  • Facilitate clinical dialogue that compels the customer to act on behalf of their patients and engage the entire account to understand any obstacles that exist to provide appropriate solutions
  • Identify shared priorities and leverage knowledge and tactics within full account to develop a territory business plan that drives product demand by meeting the needs of key partners and ultimately their patients to drive superior results
  • Utilize your understanding of the broader healthcare landscape for account selling, including provider offices and health systems, and how decisions are made across these settings
  • Manage your territory with a business owner mindset with accountability, energy, and drive by owning the outcome of your results with a sense of urgency while staying compliant with company policies and industry regulations
  • Deliver compelling product presentations and educational discussions to support patient care decisions by utilizing all approved resources in line with company training and compliance requirements
  • Collaborate as a positive energy multiplier cross-functionally with colleagues in marketing, market access, and other teams to support customer needs and win together
  • Operate with an enterprise mindset to gather and share customer insights, feedback, and questions to help Invivyd continuously improve how we serve providers and patients
  • Collaborate with cross-functional partners on overall account and territory strategy to maximize internal/external knowledge on how to access products and services
  • Aggregate customer, market data, and insights to effectively apply multiple channels to drive total selling engagements
  • Utilize data driven approach to prioritize customers/accounts to maximize impact aligned to strategic plan

Invivyd develops antibody-based therapies to protect immunocompromised people from viral threats. It discovers and optimizes monoclonal antibodies using viral surveillance, predictive modeling, and antibody engineering, aiming to prevent infections such as COVID-19 in high-risk groups. Its lead candidate VYD222 targets prevention of symptomatic COVID-19 in transplant recipients and people with blood cancers. The company plans to commercialize these antibodies through development, approvals, and partnerships, while pursuing government funding to support research for vulnerable populations.

Company Size

51-200

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

2020

Simplify Jobs

Simplify's Take

What believers are saying

  • PEMGARDA Q4 2025 revenue hit $17.2M, up 31% sequentially.
  • VYD2311 Phase 3 trial fully enrolled, data due mid-2026 with FDA Fast Track.
  • Appointed Harvard epidemiologist Michael Mina as Chief Medical Officer.

What critics are saying

  • Kahn Swick & Foti investigates officers over Adagio's 2021 IPO.
  • Low COVID-19 attack rates fail VYD2311 trial by mid-2026.
  • FDA revokes PEMGARDA EUA due to NB.1.8.1 variant escape in 2026.

What makes Invivyd unique

  • Proprietary platform combines viral surveillance, predictive modeling, and antibody engineering.
  • Develops vaccine-alternative monoclonal antibodies for immunocompromised patients.
  • Targets COVID-19, RSV, measles with pediatric-first approach via REVOLUTION program.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Invivyd who can refer or advise you

Benefits

Remote Work Options

Professional Development Budget

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-5%

2 year growth

-1%
Yahoo Finance
Mar 5th, 2026
Invivyd eyes mid-2026 data for COVID antibody VYD2311 as PEMGARDA revenue jumps 31%

Invivyd reported Q4 2025 earnings, highlighting strategic progress in monoclonal antibody prophylaxis as an alternative to COVID-19 vaccine boosting. The company's Declaration study for VYD2311 reached target enrolment of approximately 1,770 subjects, with mid-year 2026 remaining the target for pivotal data. PEMGARDA revenue grew 31% sequentially, supporting infrastructure development ahead of a potential VYD2311 launch. Management expects to decide on expanding the trial by roughly 30% in April to ensure statistical power if community attack rates fluctuate. The company reported cash of $226.7 million, providing runway through the mid-2026 data readout. Invivyd is expanding into long COVID and post-vaccine syndrome, whilst developing RSV and measles programmes with a paediatric-first approach. Management cited COVID-19 community attack rates as the primary external risk factor.

Yahoo Finance
Mar 5th, 2026
Invivyd appoints Harvard epidemiologist Michael Mina as chief medical officer

Invivyd has appointed Michael Mina, M.D., Ph.D., as Chief Medical Officer. Dr Mina is a former assistant professor of epidemiology, immunology and infectious disease at Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and Brigham and Women's Hospital. Dr Mina gained prominence during the COVID pandemic, advising governments on testing policies and leading the US government's Home Test-to-Treat Programme. His research includes discovering measles-induced "immune amnesia" and investigating antibody responses to vaccines and pathogens. He has published over 100 scientific papers with more than 10,000 citations. The appointment comes as Invivyd works to expand its pipeline of monoclonal antibodies for infectious disease prevention, including COVID, RSV and measles.

Yahoo Finance
Mar 5th, 2026
Invivyd reports $17.2M Q4 revenue for PEMGARDA, raises $200M to fund VYD2311 COVID trial

Invivyd reported fourth quarter 2025 net product revenue of $17.2 million for PEMGARDA (pemivibart), representing 25% year-over-year growth and 31% quarter-over-quarter growth. Full-year revenue more than doubled whilst operating expenses were reduced by nearly half. The company ended 2025 with $226.7 million in cash after raising over $200 million in financing transactions during the second half of the year. Invivyd has initiated the DECLARATION Phase 3 pivotal trial of VYD2311, a vaccine-alternative antibody to prevent COVID, with top-line data expected mid-2026. The FDA granted Fast Track designation for VYD2311 in December 2025. The trial has achieved full enrolment and an independent data monitoring committee has recommended allowing pregnant and breastfeeding women to participate. A potential trial re-sizing decision could occur in April.

TipRanks
Nov 17th, 2025
Invivyd Announces Common Stock Offering

Invivyd announced an underwritten public offering of its common stock, with all shares offered by the company. The proceeds will be used for commercial preparedness for VYD2311, R&D for pipeline programs like respiratory syncytial virus and measles, advancement of the SPEAR Study Group on monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome, and general corporate purposes. Cantor is the sole book-running manager for the offering.

Stock Titan
Aug 22nd, 2025
Invivyd Closes $57.5M Public Offering

Invivyd has announced the successful closing of a public offering, raising $57.5 million. The underwriter also fully exercised their option to purchase additional shares.